Clinical Trial Update: A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled trial assessing safety, reactogenicity, and immunogenicity of GamFluVac.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• GamFluVac

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: Healthy Volunteers | Phase 2 | Status: COMPLETED